Summary & Overview
CPT 81462: Genomic Sequence Analysis Panel for Solid Organ Neoplasms
CPT code 81462 represents a genomic sequence analysis panel for solid organ neoplasms, utilizing cell-free nucleic acids to detect sequence variants, copy number changes, and rearrangements. This advanced molecular assay is pivotal in oncology, offering clinicians critical insights into tumor genetics and guiding personalized treatment strategies. The procedure is typically performed in laboratory settings and is part of the broader category of genomic sequencing and multianalyte assays.
Major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, provide coverage for this code, reflecting its clinical importance and widespread adoption. Readers will gain an understanding of payer coverage benchmarks, recent policy updates, and the clinical context surrounding the use of 81462. The publication also explores related codes, common billing modifiers, and associated medical genetics taxonomies, offering a comprehensive overview for stakeholders in laboratory medicine, oncology, and medical genetics.
This summary provides a national perspective on the utilization and reimbursement landscape for 81462, equipping readers with essential information for navigating genomic testing in solid organ neoplasms.
CPT Code Overview
CPT code 81462 is used for genomic sequence analysis panels targeting solid organ neoplasms. This procedure analyzes cell-free nucleic acids, such as plasma, to interrogate for sequence variants, copy number variants, and rearrangements. It is classified under Genomic Sequencing Procedures and Other Molecular Multianalyte Assays. The typical site of service for this test is a laboratory setting (POS 81). This code is essential for advanced molecular diagnostics in oncology, enabling precise detection of genetic alterations in solid organ tumors.
Clinical & Coding Specifications
Clinical Context
A patient with a suspected or confirmed solid organ neoplasm, such as breast or ovarian cancer, presents to their oncologist. The clinician orders a genomic sequence analysis panel using cell-free nucleic acid from plasma to interrogate for sequence variants, copy number variants, and rearrangements. The test is performed in a laboratory setting (Place of Service 81) and is used to guide diagnosis, prognosis, or treatment decisions based on the molecular profile of the tumor. The workflow typically involves specimen collection, laboratory analysis, and interpretation by a medical genetics specialist.
Coding Specifications
-
Modifier
26: Used when reporting only the professional component of the service, such as interpretation of the genomic sequencing results by a physician. -
Modifier
TC: Used when reporting only the technical component, which includes the laboratory processing and analysis of the specimen. -
Modifier
59: Used to indicate a distinct procedural service, typically when multiple procedures are performed that are not normally reported together.
| Modifier Code | Description |
|---|